Q2 2022 Operational update: Continued strong biological

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52% - Biocon

GE Brings Good Things (Its Shares) Back to Life - WSJ

Scrip AsksWhat Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering :: Scrip

Stephens Investment Banking Quarterly Update, July 2022

IJMS Announcements

Abbott Delivers Resilient Q2, Raises Guidance

Intelligent Bio Solutions Inc. Announces Preliminary

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

NYC Real Estate Market Update Q2 2023 - Manhattan & Brooklyn - Nikki in NYC

Q2 2023 Agribusiness Earnings Highlights and Analysis

Syngenta Group Continues Momentum with Strong Growth in Q2 2022 - CropLife

VBI Vaccines Reports Full Year 2022 Financial Results - VBI Vaccines

Meta Platforms: Phase Change - by The Science of Hitting